Paid Alopecia Areata Research Study
Researchers at Stanford University are conducting a study to investigate a potential treatment for adults with severe alopecia areata.
Fast Facts
Diagnosed with Alopecia Areata for at Least 6 Months
Ages 18+
Compensation Provided
Conducted in
San Francisco, CA
Study Background
Help us learn more about a potential treatment for alopecia areata.
Alopecia areata (AA) is a common hair loss condition that may manifest as small patches of hair loss of the scalp, complete hair loss of the scalp, or complete hair loss of the entire body. Most individuals diagnosed with AA experience periods of hair loss and regrowth, which can negatively impact self esteem.
Through this research study, we will be investigating the effectiveness, safety, and tolerability of amlitelimab injections as a treatment for adults with severe AA.
Study Background
Help us learn more about a potential treatment for alopecia areata.
Alopecia areata (AA) is a common hair loss condition that may manifest as small patches of hair loss of the scalp, complete hair loss of the scalp, or complete hair loss of the entire body. Most individuals diagnosed with AA experience periods of hair loss and regrowth, which can negatively impact self esteem.
Through this research study, we will be investigating the effectiveness, safety, and tolerability of amlitelimab injections as a treatment for adults with severe AA.
Additional Information
The purpose of this research study is to investigate the effectiveness, safety, and tolerability of amlitelimab injections as a treatment for adults with severe AA.
You may qualify for a study if you meet the following criteria.
Inclusion Criteria:
- Ages 18+
- Diagnosed with alopecia areata for at least 6 months
- No other significant medical conditions (e.g., diabetes, lung disease, cancer)
- Experience hair loss affecting ≥50% of the scalp
- Not experiencing other forms of alopecia
- Body weight is between 88–331 lbs
- No known history of significant immunosuppression or suspected current significant immunosuppression
- No tumor
- No topical treatments in the last 2 weeks
- No contact immunotherapy in the last 4 weeks
This study will last approximately 56 weeks, and will consist of the following:
- 2 to 4-week screening period
- 36-week randomized treatment period, where eligible participants will be placed into groups where they will either receive the amlitelimab injections or a placebo
- 16-week safety follow-up
All study visits will be conducted in person.
As a participant, you can receive up to $75 per visit.
There is no cost for you to participate in our research study.
